Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Shares Acquired by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. increased its position in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) by 0.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 214,906 shares of the company’s stock after buying an additional 1,307 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Mineralys Therapeutics were worth $2,645,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. lifted its stake in shares of Mineralys Therapeutics by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,553 shares of the company’s stock worth $130,000 after acquiring an additional 989 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in Mineralys Therapeutics by 2.7% during the 4th quarter. Bank of New York Mellon Corp now owns 65,318 shares of the company’s stock worth $804,000 after purchasing an additional 1,711 shares during the last quarter. Verition Fund Management LLC increased its holdings in Mineralys Therapeutics by 30.6% during the 3rd quarter. Verition Fund Management LLC now owns 27,361 shares of the company’s stock worth $331,000 after purchasing an additional 6,408 shares during the last quarter. SG Americas Securities LLC raised its position in shares of Mineralys Therapeutics by 119.0% in the 4th quarter. SG Americas Securities LLC now owns 19,961 shares of the company’s stock valued at $246,000 after purchasing an additional 10,845 shares in the last quarter. Finally, PDT Partners LLC purchased a new position in shares of Mineralys Therapeutics during the 3rd quarter valued at approximately $148,000. Institutional investors and hedge funds own 84.46% of the company’s stock.

Mineralys Therapeutics Price Performance

Shares of MLYS opened at $15.00 on Friday. The stock has a market capitalization of $941.78 million, a PE ratio of -4.12 and a beta of 1.50. The business’s fifty day moving average price is $11.38 and its 200 day moving average price is $12.18. Mineralys Therapeutics, Inc. has a 12-month low of $8.24 and a 12-month high of $18.38.

Mineralys Therapeutics (NASDAQ:MLYS) last posted its quarterly earnings results on Wednesday, February 12th. The company reported ($0.98) EPS for the quarter, beating the consensus estimate of ($1.00) by $0.02. As a group, research analysts anticipate that Mineralys Therapeutics, Inc. will post -4.23 earnings per share for the current fiscal year.

Analysts Set New Price Targets

MLYS has been the subject of a number of research analyst reports. Guggenheim restated a “buy” rating on shares of Mineralys Therapeutics in a research note on Monday, February 24th. The Goldman Sachs Group dropped their target price on shares of Mineralys Therapeutics from $28.00 to $24.00 and set a “buy” rating for the company in a research report on Thursday, February 13th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of Mineralys Therapeutics in a research report on Monday, March 10th.

Insider Buying and Selling at Mineralys Therapeutics

In other news, major shareholder Samsara Biocapital Gp, Llc purchased 600,000 shares of Mineralys Therapeutics stock in a transaction dated Thursday, March 13th. The stock was bought at an average price of $13.50 per share, with a total value of $8,100,000.00. Following the completion of the acquisition, the insider now owns 5,674,916 shares in the company, valued at $76,611,366. The trade was a 11.82 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Jon Congleton sold 18,333 shares of the company’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $9.06, for a total transaction of $166,096.98. Following the transaction, the chief executive officer now owns 877,608 shares of the company’s stock, valued at $7,951,128.48. This represents a 2.05 % decrease in their position. The disclosure for this sale can be found here. 33.24% of the stock is currently owned by insiders.

Mineralys Therapeutics Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.